TRIM11 and supranuclear palsy, progressive, 1: The major limitation of our study is that our cohort size was relatively small compared to case–control GWAS in PSP15 and other neurodegenerative diseases.30, 31 Further replication of our findings in larger cohorts is desirable, including other non‐RS phenotypes such as PSP‐F, to confirm the role of TRIM11 and identify genetic determinants of clinical phenotype in PSP at other loci.